Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8294491 | 0.85 | PPARG (0.34) | GBA1 | |
| SCHEMBL1519541 | 0.85 | GBA1 (0.33) | GBA1 | |
| SCHEMBL8096547 | 0.80 | TSHR (0.44) | TSHRMEN1KMT2ALMNAHTT | |
| SCHEMBL1233246 | 0.80 | TSHR (0.44) | TSHRMEN1KMT2ALMNAHTT | |
| SCHEMBL8102884 | 0.78 | TSHR (0.46) | TSHRMEN1KMT2AMITFS1PR4 | |
| SCHEMBL13300477 | 0.73 | CA1 (0.36) | LMNA | |
| SCHEMBL26934165 | 0.72 | TSHR (0.50) | TSHRMEN1KMT2ALMNAHPGD | |
| SCHEMBL12765420 | 0.72 | CA12 (0.49) | TSHRMEN1KMT2ALMNACA12 | |
| SCHEMBL10088327 | 0.71 | RECQL (0.40) | TSHRMEN1KMT2ALMNACA12 | |
| SCHEMBL24065971 | 0.70 | TSHR (0.42) | TSHRMEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897560-B2 | Plasma protein affinity tags | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-7897560-B2 | Plasma protein affinity tags | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20100184641-A1 | Novel Plasma Protein Affinity Tags | NOVO NORDISK A/S (DK) | 2010-07-22 | — | — | US | disclosed |
| US-20100184641-A1 | Novel Plasma Protein Affinity Tags | NOVO NORDISK A/S (DK) | 2010-07-22 | — | — | US | disclosed |
| US-7541430-B2 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7541430-B2 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-20090088388-A1 | Peptides for Use In Treating Obesity | NOVO NORDISK A/S (DK) | 2009-04-02 | — | — | US | disclosed |
| US-20090088388-A1 | Peptides for Use In Treating Obesity | NOVO NORDISK A/S (DK) | 2009-04-02 | — | — | US | disclosed |
| US-20070244054-A1 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070244054-A1 | Peptides for use in treating obesity | NOVO NORDISK A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070105750-A1 | Novel plasma protein affinity tags | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
| US-20070105750-A1 | Novel plasma protein affinity tags | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184641-A1 | Novel Plasma Protein Affinity Tags | CD2BP2, HDLBP, SERPINA6 | TSHR 1995/4885MEN1 3471/4885KMT2A 4427/4885 |
| US-20070105750-A1 | Novel plasma protein affinity tags | CD2BP2, HDLBP, SERPINA6 | TSHR 1995/4885MEN1 3471/4885KMT2A 4427/4885 |
| US-20070244054-A1 | Peptides for use in treating obesity | NPY4R, GLP1R, NPY1R | TSHR 296/4885MEN1 2493/4885KMT2A 4510/4885 |
| US-20090088388-A1 | Peptides for Use In Treating Obesity | NPY4R, GLP1R, NPY1R | TSHR 296/4885MEN1 2493/4885KMT2A 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.